Improving Strategies for Management of Primary Biliary Cholangitis


In this video segment, Palak and Trivedi discuss strategies for improving the management of patients in real-world settings given recent advances in therapies and pathophysiology.

In the final segment of our HCPLive Special Report on Updates and Unmet Needs in Primary Biliary Cholangitis, Palak Trivedi, MD, PhD, and James Boyer, MD, discuss strategies for better supporting primary biliary cholangitis (PBC) patients in managing their condition. Boyer underscores the importance of early diagnosis, particularly in primary care, and advocates for increased awareness among primary care physicians about PBC and the significance of testing for anti-mitochondrial antibodies in at-risk patients. They also highlight the need to address side effects like pruritus comprehensively.

Trivedi mentions a recent initiative from the Netherlands, which involves a patient-facing document that helps patients optimize their consultations with healthcare providers. This tool aims to enhance value-based healthcare by enabling patients to better communicate their needs and concerns during medical visits, reflecting the broader goals of patient empowerment and improved disease management.

Check out the other segments in this series:

Subject Matter Experts:

  • James Boyer, MD, Ensign Professor of Medicine at Yale School of Medicine and the Founder and Emeritus Director of the Yale Liver Center.
  • Palak Trivedi, MD, PhD, Associate Professor and Honorary Consultant Hepatologist and Clinical Research Director for Industry Engagement at the University of Birmingham. Also serves as an investigator on the open-label ASSURE trial of seladelpar in patients with PBC.
Related Videos
4 KOLs are featured in this series
4 KOLs are featured in this series
M. Safwan Badr, MD: Novel Treatments for Central Sleep Apnea in Last 10 Years
Video 4 - Featuring 3 KOLs in, "Implementing Treat to Target in the Long-term in Inflammatory Bowel Disease "
Video 3 - Featuring 3 KOLs in, "How important is transmural healing as a treatment target in UC and CD?   Where does intestinal ultrasound fit in CD management?  "
How Elite Athletes Can Optimize Sleep for Peak Performance, with Jesse D. Cook, PhD
Boadie Dunlop, MD, Weighs in on FDA Advisory Vote on Lykos’ MDMA
HCPLive Five at ADA 2024 | Image Credit: HCPLive
© 2024 MJH Life Sciences

All rights reserved.